Corbus Pharmaceuticals Holdings, Inc. Other Nonoperating Income (Expense)
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Other Nonoperating Income (Expense) of -$11.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was -$11.00K, a 106.25% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was -$67.00K, a 106.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $1.00K, a 99.92% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$50.00K, a 125.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for fiscal 2025 was $1.24M, a 69.48% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for fiscal 2024 was $4.07M, a 51.08% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for fiscal 2023 was $2.70M.
- Corbus Pharmaceuticals Holdings, Inc. other nonoperating income (expense) for fiscal 2022 was -$48.77K, a 100.41% decline from fiscal 2021.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 3 month as first filed | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 6 month as first filed | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 9 month as first filed | Other Nonoperating Income (Expense) 12 month | Other Nonoperating Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.00K 10-Q · filed 2026-08-06 | -$78.00K 10-Q · filed 2026-08-06 | -$77.00K derived: sum of 3 quarters · filed 2026-08-06 | -$127.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$67.00K 10-Q · filed 2026-05-12 | -$66.00K derived: sum of 2 quarters · filed 2026-05-12 | -$116.00K derived: sum of 3 quarters · filed 2026-05-12 | $60.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$49.00K derived: sum of 2 quarters · filed 2026-03-09 | $127.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.24M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$50.00K 10-Q · filed 2025-11-12 | $126.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.24M 10-Q · filed 2025-11-12 | $2.54M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $176.00K 10-Q · filed 2026-08-06 | $1.29M 10-Q · filed 2026-08-06 | $2.59M derived: sum of 3 quarters · filed 2026-08-06 | $2.79M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.12M 10-Q · filed 2026-05-12 | $2.41M derived: sum of 2 quarters · filed 2026-05-12 | $2.61M derived: sum of 3 quarters · filed 2026-05-12 | $2.65M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.50M derived: sum of 2 quarters · filed 2026-03-09 | $1.54M derived: sum of 3 quarters · filed 2026-03-09 | $4.07M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-12 | $713.00K 10-Q · filed 2024-11-07 | $243.00K derived: sum of 2 quarters · filed 2025-11-12 | $2.78M 10-Q · filed 2025-11-12 | $4.32M 10-Q · filed 2024-11-07 | $4.84M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $43.00K 10-Q · filed 2025-08-05 | $695.00K 10-Q · filed 2024-08-06 | $2.58M 10-Q · filed 2025-08-05 | $3.60M 10-Q · filed 2024-08-06 | $4.64M derived: sum of 3 quarters · filed 2025-08-05 | $4.86M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $2.54M 10-Q · filed 2025-05-06 | $2.91M 10-Q · filed 2024-05-07 | $4.60M derived: sum of 2 quarters · filed 2025-05-06 | $4.82M derived: sum of 3 quarters · filed 2025-05-06 | $5.00M derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.28M derived: sum of 2 quarters · filed 2025-03-11 | $2.47M derived: sum of 3 quarters · filed 2025-03-11 | $2.70M 10-K · filed 2025-03-11 | $3.39M 10-K · filed 2024-03-12 | |||
| 2023-09-30 | $218.00K 10-Q · filed 2024-11-07 | $217.54K 10-Q · filed 2023-11-07 | $401.00K derived: sum of 2 quarters · filed 2024-11-07 | $630.00K 10-Q · filed 2024-11-07 | $629.71K 10-Q · filed 2023-11-07 | $906.06K derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $183.00K 10-Q · filed 2024-08-06 | $182.66K 10-Q · filed 2023-08-08 | $412.00K 10-Q · filed 2024-08-06 | $412.16K 10-Q · filed 2023-08-08 | $688.06K derived: sum of 3 quarters · filed 2024-08-06 | $765.77K derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $229.51K 10-Q · filed 2024-05-07 | $505.06K derived: sum of 2 quarters · filed 2024-05-07 | $582.77K derived: sum of 3 quarters · filed 2024-05-07 | $374.08K derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $275.55K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $353.26K derived: sum of 2 quarters · filed 2024-03-12 | $144.58K derived: sum of 3 quarters · filed 2024-03-12 | -$48.77K 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $77.71K 10-Q · filed 2023-11-07 | -$130.97K derived: sum of 2 quarters · filed 2023-11-07 | -$324.32K 10-Q · filed 2023-11-07 | -$214.66K derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$208.68K 10-Q · filed 2023-08-08 | -$402.03K 10-Q · filed 2023-08-08 | -$292.37K derived: sum of 3 quarters · filed 2023-08-08 | $11.74M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | -$193.35K 10-Q · filed 2023-05-09 | -$83.69K derived: sum of 2 quarters · filed 2023-05-09 | $11.95M derived: sum of 3 quarters · filed 2023-05-09 | $11.72M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $109.66K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $12.14M derived: sum of 2 quarters · filed 2023-03-07 | $11.92M derived: sum of 3 quarters · filed 2023-03-07 | $11.90M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $12.03M 10-Q · filed 2022-11-08 | $11.81M derived: sum of 2 quarters · filed 2022-11-08 | $11.79M 10-Q · filed 2022-11-08 | $25.06M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$227.61K 10-Q · filed 2022-08-09 | -$242.70K 10-Q · filed 2022-08-09 | $13.02M derived: sum of 3 quarters · filed 2022-08-09 | $13.02M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$15.09K 10-Q · filed 2022-05-10 | $13.25M derived: sum of 2 quarters · filed 2022-05-10 | $13.25M derived: sum of 3 quarters · filed 2022-05-10 | |||||
| 2020-12-31 | $13.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $13.26M derived: sum of 2 quarters · filed 2022-03-08 | $13.27M 10-K · filed 2022-03-08 | |||||
| 2020-09-30 | -$4.97K 10-Q · filed 2021-11-12 | $4.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |